Should warfarin-based triple therapy be ditched in AF patients undergoing PCI?

Using two lower dose rivaroxaban regimens with either a single P2Y12 inhibitor or standard dual antiplatelet therapy (DAPT) instead of a combination of warfarin and DAPT reduced clinically significant bleeding rates in patients with atrial fibrillation (AF) undergoing PCI, new findings from PIONEER AF-PCI reveal. The findings could signal an end to warfarin-based triple oral ...

Already a member?

Login to keep reading.

© 2021 the limbic